Lorundrostat vs Vicadrostat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Aldosterone synthase (CYP11B2) · full Hypertension pipeline

Lorundrostat

Developed by Mineralys Therapeutics and partners

Phase 3 in Hypertensionsmall molecule
Reliable signal

NCT05769608 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled trial in 285 patients with uncontrolled hypertension that measured 24-hour ambulatory systolic blood pressure, the standard efficacy measure for this disease. The 50 mg lorundrostat dose lowered ambulatory blood pressure significantly more than placebo at week 12.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001) (met)

Result source: NCT06153693

Vicadrostat

Developed by Boehringer Ingelheim

Phase 3 in Hypertensionsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2029 · NCT07064473 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLorundrostatVicadrostat
Seated SBP, change—Not posted · NCT06153693—Trial running · NCT07064473
24-hour ambulatory SBP, change—Not posted · NCT06153693—Trial running · NCT07064473
Seated DBP, change—Not posted · NCT06153693—Trial running · NCT07064473

Seated SBP, change

Lorundrostat
—Not posted · NCT06153693
Vicadrostat
—Trial running · NCT07064473

24-hour ambulatory SBP, change

Lorundrostat
—Not posted · NCT06153693
Vicadrostat
—Trial running · NCT07064473

Seated DBP, change

Lorundrostat
—Not posted · NCT06153693
Vicadrostat
—Trial running · NCT07064473
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Vicadrostat: no structured comparison results are available for Hypertension.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lorundrostat: 2 of 4 rows · Vicadrostat: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLorundrostat
Dropout rate
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Discontinued due to AEs
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Serious AEs
3.4%
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Most frequent reported AEs
hyperkalaemia 15.5% (placebo 3.5%)
glomerular filtration rate decreased 10.3% (placebo 3.5%)
hyponatraemia 5.2% (placebo 5.3%)
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lorundrostat

AOBP SBP -9.253 vs -1.755 placebo mmHg @ 4wk
absolute change · mmHg
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
Ambulatory SBP -7.9 mmHg @ 12wklorundrostat 50 mg arm
absolute change · mmHg
No placebo or comparator arm
NCT05769608 · Phase 2 · sponsor-reported, not registry data

Chronic Kidney Disease

Shared mechanism: Aldosterone synthase (CYP11B2) · full Chronic Kidney Disease pipeline

Lorundrostat

Developed by Mineralys Therapeutics and partners

Phase 2 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT06150924 · Phase 2 · completed

Explore-CKD was a randomized, double-blind, placebo-controlled, two-period crossover Phase 2 trial of lorundrostat 25 mg on top of an SGLT2 inhibitor in about 60 patients with hypertension and albuminuric chronic kidney disease. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure at week 4: -7.5 mmHg (p=0.0024), and the sponsor states the trial met the primary endpoint. Sources: CT.gov posted results and the Mineralys press release filed on SEC Form 8-K.

Reported efficacy

Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4 (Baseline to Week 4): Automated office systolic blood pressure at week 4: lorundrostat 25 mg -9.25 mmHg vs placebo -1.76 mmHg (CT.gov LS means, n=58 per period); placebo-adjusted -7.5 mmHg (p=0.0024) (Mineralys release, 17 Jun 2025, SEC 8-K). (met)

Result source: NCT06150924

Vicadrostat

Developed by Boehringer Ingelheim

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT06531824 · Phase 3 · active, not recruiting

This was a randomized, quadruple-masked Phase 3 trial with 8371 participants. Its primary endpoint was not met according to the sponsor's announcement of 2026-09-01. A well-designed trial whose primary comparison was not met, or only partly met, is graded moderate.

Next expected readout: December 2026 · NCT06531824 (registry estimate)

Reported efficacy

Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death. (up to 4 years): Discontinued by Boehringer Ingelheim on an independent Data Monitoring Committee recommendation: accumulating data did not support a meaningful expectation of benefit on the primary composite endpoint vs empagliflozin alone (September 2026). (missed)

Result source: NCT06531824

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointLorundrostatVicadrostat
Kidney composite outcome—Not reported—Trial running · NCT06531824
UACR, % change—Not reported-38.5% vs -6.4%−32.1 vs placebo20 mg · wk 14 · n 121NCT05182840
8 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -42.5% vs -6.4% 10 mg · wk 14 · n 121 · Phase 2 · primary NCT05182840
  • -39.1% vs -2.6% 10 mg · wk 14 · n 61 · Phase 2 · primary NCT05182840
  • -20.9% vs -6.4% 3 mg · wk 14 · n 128 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840
eGFR slope—Not reported—Trial running · NCT06531824
Haemoglobin, change—Not reported—Trial running · NCT06531824

Kidney composite outcome

Lorundrostat
—Not reported
Vicadrostat
—Trial running · NCT06531824

UACR, % change

Lorundrostat
—Not reported
Vicadrostat
-38.5% vs -6.4%−32.1 vs placebo20 mg · wk 14 · n 121NCT05182840
8 other results
  • -36.6% vs -2.6% 20 mg · wk 14 · n 59 · Phase 2 · primary NCT05182840
  • -42.5% vs -6.4% 10 mg · wk 14 · n 121 · Phase 2 · primary NCT05182840
  • -39.1% vs -2.6% 10 mg · wk 14 · n 61 · Phase 2 · primary NCT05182840
  • -20.9% vs -6.4% 3 mg · wk 14 · n 128 · Phase 2 · primary NCT05182840
  • -22.4% vs -2.6% 3 mg · wk 14 · n 65 · Phase 2 · primary NCT05182840
  • -19% vs -10.6% 10 mg + 3 mg · wk 14 · n 63 · Phase 2 · primary NCT05182840
  • -45.9% vs -10.6% 10 mg + 10 mg · wk 14 · n 60 · Phase 2 · primary NCT05182840
  • -40.3% vs -10.6% 10 mg + 20 mg · wk 14 · n 62 · Phase 2 · primary NCT05182840

eGFR slope

Lorundrostat
—Not reported
Vicadrostat
—Trial running · NCT06531824

Haemoglobin, change

Lorundrostat
—Not reported
Vicadrostat
—Trial running · NCT06531824
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Lorundrostat: 2 of 4 rows · Vicadrostat: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLorundrostatVicadrostat
Dropout rate
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
—20 mga
NCT05182840 · Phase 2
show 5 more results
—10 mg + 10 mg
NCT05182840 · Phase 2 · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · combination
—10 mg
NCT05182840 · Phase 2
—3 mg
NCT05182840 · Phase 2
Discontinued due to AEs
—
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
—20 mga
NCT05182840 · Phase 2
show 5 more results
—10 mg + 10 mg
NCT05182840 · Phase 2 · combination
—10 mg + 20 mg
NCT05182840 · Phase 2 · combination
—10 mg + 3 mg
NCT05182840 · Phase 2 · combination
—10 mg
NCT05182840 · Phase 2
—3 mg
NCT05182840 · Phase 2
Serious AEs
3.4%
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
8.3%20 mga
NCT05182840 · Phase 2
show 5 more results
9.6%10 mg + 10 mg
NCT05182840 · Phase 2 · combination
6.8%10 mg + 20 mg
NCT05182840 · Phase 2 · combination
5.3%10 mg + 3 mg
NCT05182840 · Phase 2 · combination
5.6%10 mg
NCT05182840 · Phase 2
4.3%3 mg
NCT05182840 · Phase 2
Most frequent reported AEs
hyperkalaemia 15.5% (placebo 3.5%)
glomerular filtration rate decreased 10.3% (placebo 3.5%)
hyponatraemia 5.2% (placebo 5.3%)
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2
20 mga
hyperkalaemia 23.6% (placebo 5.5%)
glomerular filtration rate decreased 8.3% (placebo 4.1%)
upper respiratory tract infection 4.2% (placebo 2.7%)
NCT05182840 · Phase 2
show 5 more results
10 mg + 10 mg
hyperkalaemia 15.1% (placebo 5.5%)
glomerular filtration rate decreased 11% (placebo 4.1%)
hypotension 5.5% (placebo 0%)
NCT05182840 · Phase 2 · combination
10 mg + 20 mg
glomerular filtration rate decreased 9.5% (placebo 4.1%)
hyperkalaemia 9.5% (placebo 5.5%)
upper respiratory tract infection 5.4% (placebo 2.7%)
NCT05182840 · Phase 2 · combination
10 mg + 3 mg
hyperkalaemia 6.6% (placebo 5.5%)
glomerular filtration rate decreased 5.3% (placebo 4.1%)
cortisol decreased 2.6% (placebo 0%)
NCT05182840 · Phase 2 · combination
10 mg
glomerular filtration rate decreased 9.9% (placebo 4.1%)
hyperkalaemia 9.9% (placebo 5.5%)
cortisol decreased 5.6% (placebo 0%)
NCT05182840 · Phase 2
3 mg
hyperkalaemia 11.4% (placebo 5.5%)
cortisol decreased 4.3% (placebo 0%)
upper respiratory tract infection 2.9% (placebo 2.7%)
NCT05182840 · Phase 2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lorundrostat

AOBP SBP -9.253 vs -1.755 placebo mmHg @ 4wk
absolute change · mmHg
NCT06150924 · Phase 2 · pooled · Chronic Kidney Disease, Hypertension · phase 2

Vicadrostat

UACR -0.487 vs -0.066 placebo mg @ 14wk20 mg
absolute change · mg
NCT05182840 · Phase 2
show 8 more results
-0.455 vs -0.027 placebo mg @ 14wk20 mg
NCT05182840 · Phase 2
-0.553 vs -0.066 placebo mg @ 14wk10 mg
NCT05182840 · Phase 2
-0.496 vs -0.027 placebo mg @ 14wk10 mg
NCT05182840 · Phase 2
-0.21 vs -0.112 Empagliflozin mg @ 14wk10 mg + 3 mg
NCT05182840 · Phase 2 · combination
-0.614 vs -0.112 Empagliflozin mg @ 14wk10 mg + 10 mg
NCT05182840 · Phase 2 · combination
-0.516 vs -0.112 Empagliflozin mg @ 14wk10 mg + 20 mg
NCT05182840 · Phase 2 · combination
-0.235 vs -0.066 placebo mg @ 14wk3 mg
NCT05182840 · Phase 2
-0.254 vs -0.027 placebo mg @ 14wk3 mg
NCT05182840 · Phase 2
UACR -38.5% (n=121) vs -6.4% (n=133) placebo @ 14wk20 mg
percent change · % of baseline
NCT05182840 · Phase 2
show 8 more results
-36.6% (n=59) vs -2.6% (n=69) placebo @ 14wk20 mg
NCT05182840 · Phase 2
-42.5% (n=121) vs -6.4% (n=133) placebo @ 14wk10 mg
NCT05182840 · Phase 2
-39.1% (n=61) vs -2.6% (n=69) placebo @ 14wk10 mg
NCT05182840 · Phase 2
-19% (n=63) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 3 mg
NCT05182840 · Phase 2 · combination
-45.9% (n=60) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 10 mg
NCT05182840 · Phase 2 · combination
-40.3% (n=62) vs -10.6% (n=64) Empagliflozin @ 14wk10 mg + 20 mg
NCT05182840 · Phase 2 · combination
-20.9% (n=128) vs -6.4% (n=133) placebo @ 14wk3 mg
NCT05182840 · Phase 2
-22.4% (n=65) vs -2.6% (n=69) placebo @ 14wk3 mg
NCT05182840 · Phase 2
UACR 30 54.5% (n=121) vs 18% (n=133) placebo @ 14wk20 mg
responder rate · % of participants
NCT05182840 · Phase 2 · converted to % from 66 Participants as posted
show 35 more results
47.1% (n=121) vs 17.3% (n=133) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 57 Participants as posted
60.3% (n=121) vs 23.3% (n=133) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 73 Participants as posted
53.8% (n=106) vs 18.1% (n=127) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 57 Participants as posted
50.8% (n=59) vs 14.5% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 30 Participants as posted
42.4% (n=59) vs 13% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 25 Participants as posted
54.2% (n=59) vs 20.3% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 32 Participants as posted
50% (n=50) vs 13.6% (n=66) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 25 Participants as posted
60.3% (n=121) vs 18% (n=133) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 73 Participants as posted
51.2% (n=121) vs 17.3% (n=133) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 62 Participants as posted
55.4% (n=121) vs 23.3% (n=133) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 67 Participants as posted
57.9% (n=107) vs 18.1% (n=127) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 62 Participants as posted
50.8% (n=61) vs 14.5% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 31 Participants as posted
45.9% (n=61) vs 13% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 28 Participants as posted
50.8% (n=61) vs 20.3% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 31 Participants as posted
50% (n=56) vs 13.6% (n=66) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 28 Participants as posted
33.3% (n=63) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · combination · converted to % from 21 Participants as posted
70% (n=60) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · combination · converted to % from 42 Participants as posted
58.1% (n=62) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · combination · converted to % from 36 Participants as posted
33.3% (n=63) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · combination · converted to % from 21 Participants as posted
56.7% (n=60) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · combination · converted to % from 34 Participants as posted
51.6% (n=62) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · combination · converted to % from 32 Participants as posted
36.5% (n=63) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · combination · converted to % from 23 Participants as posted
60% (n=60) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · combination · converted to % from 36 Participants as posted
66.1% (n=62) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · combination · converted to % from 41 Participants as posted
33.3% (n=63) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · combination · converted to % from 21 Participants as posted
66.7% (n=51) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · combination · converted to % from 34 Participants as posted
57.1% (n=56) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · combination · converted to % from 32 Participants as posted
31.3% (n=128) vs 18% (n=133) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 40 Participants as posted
31.3% (n=128) vs 17.3% (n=133) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 40 Participants as posted
35.2% (n=128) vs 23.3% (n=133) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 45 Participants as posted
32.3% (n=124) vs 18.1% (n=127) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 40 Participants as posted
29.2% (n=65) vs 14.5% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 19 Participants as posted
29.2% (n=65) vs 13% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 19 Participants as posted
33.8% (n=65) vs 20.3% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 22 Participants as posted
31.1% (n=61) vs 13.6% (n=66) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 19 Participants as posted
UACR 15 66.9% (n=121) vs 34.6% (n=133) placebo @ 14wk20 mg
responder rate · % of participants
NCT05182840 · Phase 2 · converted to % from 81 Participants as posted
show 35 more results
57.9% (n=121) vs 33.1% (n=133) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 70 Participants as posted
70.2% (n=121) vs 39.8% (n=133) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 85 Participants as posted
66% (n=106) vs 34.6% (n=127) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 70 Participants as posted
66.1% (n=59) vs 31.9% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 39 Participants as posted
54.2% (n=59) vs 29% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 32 Participants as posted
69.5% (n=59) vs 36.2% (n=69) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 41 Participants as posted
64% (n=50) vs 30.3% (n=66) placebo @ 14wk*20 mg
NCT05182840 · Phase 2 · converted to % from 32 Participants as posted
67.8% (n=121) vs 34.6% (n=133) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 82 Participants as posted
58.7% (n=121) vs 33.1% (n=133) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 71 Participants as posted
71.9% (n=121) vs 39.8% (n=133) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 87 Participants as posted
66.4% (n=107) vs 34.6% (n=127) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 71 Participants as posted
57.4% (n=61) vs 31.9% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 35 Participants as posted
52.5% (n=61) vs 29% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 32 Participants as posted
67.2% (n=61) vs 36.2% (n=69) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 41 Participants as posted
55.6% (n=63) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · combination · converted to % from 35 Participants as posted
78.3% (n=60) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · combination · converted to % from 47 Participants as posted
67.7% (n=62) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · combination · converted to % from 42 Participants as posted
55.6% (n=63) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · combination · converted to % from 35 Participants as posted
65% (n=60) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · combination · converted to % from 39 Participants as posted
61.3% (n=62) vs 37.5% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · combination · converted to % from 38 Participants as posted
61.9% (n=63) vs 43.8% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · combination · converted to % from 39 Participants as posted
76.7% (n=60) vs 43.8% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · combination · converted to % from 46 Participants as posted
71% (n=62) vs 43.8% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · combination · converted to % from 44 Participants as posted
57.1% (n=56) vs 30.3% (n=66) placebo @ 14wk*10 mg
NCT05182840 · Phase 2 · converted to % from 32 Participants as posted
55.6% (n=63) vs 39.3% (n=61) Empagliflozin @ 14wk*10 mg + 3 mg
NCT05182840 · Phase 2 · combination · converted to % from 35 Participants as posted
76.5% (n=51) vs 39.3% (n=61) Empagliflozin @ 14wk*10 mg + 10 mg
NCT05182840 · Phase 2 · combination · converted to % from 39 Participants as posted
67.9% (n=56) vs 39.3% (n=61) Empagliflozin @ 14wk*10 mg + 20 mg
NCT05182840 · Phase 2 · combination · converted to % from 38 Participants as posted
53.1% (n=128) vs 34.6% (n=133) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 68 Participants as posted
52.3% (n=128) vs 33.1% (n=133) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 67 Participants as posted
52.3% (n=128) vs 39.8% (n=133) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 67 Participants as posted
54% (n=124) vs 34.6% (n=127) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 67 Participants as posted
50.8% (n=65) vs 31.9% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 33 Participants as posted
49.2% (n=65) vs 29% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 32 Participants as posted
43.1% (n=65) vs 36.2% (n=69) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 28 Participants as posted
52.5% (n=61) vs 30.3% (n=66) placebo @ 14wk*3 mg
NCT05182840 · Phase 2 · converted to % from 32 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lorundrostat's landscape · Vicadrostat's landscape